Physiomics signs contract with Servier Group

The oncology drug development consultancy, Physiomics signed on the Servier Group, an international pharmaceutical company headquartered in France, as a new client on Friday.

Servier’s key therapy areas include cancer, with a particular emphasis on immunotherapies and monoclonal antibodies for difficult-to-treat diseases with significant unmet medical needs.

- Advertisement -

Physiomics will use its Virtual Tumour software platform to study and simulate the effect of a range of immuno-oncology combinations in development utilising Servier medicines in pre-clinical and clinical settings.

The project will be completed in the next 7-8 months, according to the forecast.

“We are delighted to have been selected by Servier, one of France’s leading pharmaceutical companies with a truly global outlook as its partner for this modelling and simulation project focused on pre-clinical and translational modelling of a novel immuno-oncology agent in development.  We look forward to working with its talented scientists,” said Physiomics CEO, Dr Jim Millen.

Physiomics’ shares fell 1% to 4.5p on the announcement of its contract with the Servier Group.

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This